Cargando…
Quantifying the real life risk profile of inhaled corticosteroids in COPD by record linkage analysis
BACKGROUND: Inhaled corticosteroids (ICS), especially when prescribed in combination with long-acting β(2) agonists have been shown to improve COPD outcomes. Although there is consistent evidence linking ICS with adverse effects such as pneumonia, the complete risk profile is unclear with conflictin...
Autores principales: | Flynn, Rob W, MacDonald, Thomas M, Hapca, Adrian, MacKenzie, Isla S, Schembri, Stuart |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239312/ https://www.ncbi.nlm.nih.gov/pubmed/25407604 http://dx.doi.org/10.1186/s12931-014-0141-y |
Ejemplares similares
-
The effect of changes to GOLD severity stage on long term morbidity and mortality in COPD
por: Flynn, Robert W. V., et al.
Publicado: (2018) -
Inhaled Corticosteroids and the Lung Microbiome in COPD
por: Keir, Holly R., et al.
Publicado: (2021) -
Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease—The Shifting Treatment Paradigm
por: Wilkie, Morven, et al.
Publicado: (2015) -
Inhaled corticosteroids in COPD and the risk of serious pneumonia
por: Suissa, Samy, et al.
Publicado: (2013) -
Inhaled corticosteroids in COPD: Personalising the therapeutic choice
por: Shaw, J A, et al.
Publicado: (2018)